NCT00351507已完成3 期
A Double-blind, Crossover, Placebo-Controlled, Multiple-dose Study to Evaluate the Effects of Vildagliptin on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Effect on gastric emptying
研究概览
简要总结
This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 35 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with type 2 diabetes for at least 6 months
- •Blood glucose criteria must be met
- •BMI in the range 22-40
排除标准
- •History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- •Use of thiazolidinediones or need for insulin within 3 months prior to screening
- •Significant concomitant diseases or complications of diabetes
- •High fasting triglycerides as defined by the protocol
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Effect on gastric emptying
次要结局
- Effect on gastric volume
- Effect on satiety
- Effect on endogenous glucose appearance, glucose appearance and glucose disposal
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese VolunteersHealthyNCT00419887Novartis60
已完成
2 期
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With GastroparesisGastroparesisNCT00861809GlaxoSmithKline11
已完成
3 期
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 DiabetesDiabetes Mellitus Type 2NCT00809705Hoffmann-La Roche60
Unknown
2 期
PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)Insulin-dependent Gestational DiabetesNCT01018602Institut fur Diabetesforschung, Munich, Germany140
已完成
3 期
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00390520Novartis28